Antithrombotic and thrombolytic therapy: from evidence to application: the Seventh ACCP Conference on Antithrombotic

Holger J Schünemann1, Deborah Cook, Jeremy Grimshaw

  • 1Department of Medicine, University at Buffalo, ECMC-CC142, 462 Grider St, Buffalo, NY 14215, USA. HJS@buffalo.edu

Chest
|September 24, 2004
PubMed

Insights

Implementing practice guidelines for antithrombotic and thrombolytic therapy requires careful resource allocation. Computer reminders and patient-mediated interventions show promise, but more research is needed for consistent benefits.

Area of Science:

  • Medical Guidelines
  • Evidence-Based Medicine
  • Thrombosis Management

Background:

  • Practice guidelines are crucial for optimizing antithrombotic and thrombolytic therapy.
  • Effective implementation strategies are essential for guideline uptake and patient benefit.
  • The 7th ACCP Conference on Antithrombotic and Thrombolytic Therapy addressed these implementation challenges.

Purpose of the Study:

  • To evaluate the effectiveness of various implementation strategies for practice guidelines.
  • To guide resource allocation for promoting the adoption of antithrombotic and thrombolytic therapy guidelines.
  • To identify strategies with consistent and unequivocal benefits.

Main Methods:

  • Review of implementation strategies based on Grade 1 and Grade 2 recommendations.
  • Assessment of resource investment versus benefit for different strategies.
  • Consideration of feasibility, acceptability, and cost in practice settings.

Main Results:

  • Distribution of educational material is recommended with appreciable resources (Grade 2B).
  • Computer reminders (Grade 2A) and patient-mediated interventions (Grade 2B) are suggested for significant resource investment.
  • Educational meetings, audit and feedback, and outreach visits require fewer resources (Grade 2B).

Conclusions:

  • Few implementation strategies offer unequivocal and consistent benefits for resource investment.
  • Optimizing antithrombotic and thrombolytic therapy requires further research into effective guideline implementation.
  • Tailoring strategies to practice settings is important for successful guideline adoption.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...